Juno Therapeutics Inc.'s JCAR017 demonstrated a reduction in disease in 74% of patients in a phase 1 trial to treat relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
The TRANSCEND study has treated 91 patients who were put into two groups, the core group and the full analysis group. The patients in the core group received two doses of the drug — 100 million cells and 50 million cells.
For the core group, which included 67 patients, the three-month overall response rate was 74%, with 68% of patients showing no signs of the disease. Across doses, 80% of patients with complete response at three months stayed in complete response at six months and 92% of patients in response at six months remain in response as of Oct. 9.
Median duration of response across doses was 9.2 months. However, the median durability of complete response has not been reached.
Juno is jointly developing JCAR017 with Celgene Corp. under a collaboration aimed at developing treatments for patients with cancer and autoimmune diseases using T-cell therapeutic strategies.
The company presented the updated data at the 59th American Society of Hematology annual meeting.